1. (a) The Secretary shall establish guidelines for the co-prescribing of opioid overdose reversal drugs that are applicable to all licensed health care providers in the State who are authorized by law to prescribe a monitored prescription drug, as defined in § 21-2A-01 of this article.

2. (b) The guidelines established under subsection (a) of this section shall address the co-prescribing of opioid overdose reversal drugs for patients who are:

   1. (1) At an elevated risk of overdose; and

   2. (2)

      1. (i) Receiving opioid therapy for chronic pain;
      2. (ii) Receiving a prescription for benzodiazepines; or
      3. (iii) Being treated for opioid use disorders.

Added by Acts 2017, c. 571, § 1, eff. June 1, 2017; Acts 2017, c. 572, § 1, eff. June 1, 2017.